Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M39,322Revenue (TTM) $M4,732Net Margin (%)16.5Altman Z-Score12.1
Enterprise Value $M38,000EPS (TTM) $6.8Operating Margin %25.7Piotroski F-Score6
P/E(ttm)54.9Beneish M-Score-2.8Pre-tax Margin (%)25.7Higher ROA y-yN
Price/Book8.610-y EBITDA Growth Rate %--Quick Ratio3.3Cash flow > EarningsY
Price/Sales9.15-y EBITDA Growth Rate %--Current Ratio3.6Lower Leverage y-yY
Price/Free Cash Flow51.4y-y EBITDA Growth Rate %0.9ROA % (ttm)13.2Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)20.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M105ROIC % (ttm)24.6Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNGeorge Soros 2016-09-30 Buy 0.02%$358.5 - $441.37
($401.14)
$ 372.83-7%New holding1,381
REGNJoel Greenblatt 2016-09-30 Reduce-0.02%$358.5 - $441.37
($401.14)
$ 372.83-7%Reduce -17.93%24,745
REGNRon Baron 2016-09-30 Reduce$358.5 - $441.37
($401.14)
$ 372.83-7%Reduce -1.26%4,924
REGNMario Gabelli 2016-09-30 Reduce$358.5 - $441.37
($401.14)
$ 372.83-7%Reduce -60.20%529
REGNKen Fisher 2016-09-30 Add$358.5 - $441.37
($401.14)
$ 372.83-7%Add 1.14%620
REGNJoel Greenblatt 2016-06-30 Add0.12%$331.05 - $427.2
($384.74)
$ 372.83-3%Add 1094.10%30,151
REGNVanguard Health Care Fund 2016-06-30 Add0.08%$331.05 - $427.2
($384.74)
$ 372.83-3%Add 3.46%3,279,190
REGNMario Gabelli 2016-06-30 Reduce$331.05 - $427.2
($384.74)
$ 372.83-3%Reduce -1.04%1,329
REGNRon Baron 2016-06-30 Reduce$331.05 - $427.2
($384.74)
$ 372.83-3%Reduce -0.48%4,987
REGNVanguard Health Care Fund 2016-03-31 Add0.71%$359.68 - $542.87
($414.39)
$ 372.83-10%Add 38.98%3,169,490
REGNJoel Greenblatt 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 372.83-10%Reduce -39.26%2,525
REGNRon Baron 2016-03-31 Reduce-0.01%$359.68 - $542.87
($414.39)
$ 372.83-10%Reduce -32.86%5,011
REGNKen Fisher 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 372.83-10%Reduce -0.33%613
REGNMario Gabelli 2016-03-31 Reduce$359.68 - $542.87
($414.39)
$ 372.83-10%Reduce -2.54%1,343
REGNVanguard Health Care Fund 2015-12-31 Reduce-0.17%$459.82 - $587.09
($543.11)
$ 372.83-31%Reduce -6.84%2,280,494
REGNJoel Greenblatt 2015-12-31 Buy 0.02%$459.82 - $587.09
($543.11)
$ 372.83-31%New holding4,157
REGNMario Gabelli 2015-12-31 Reduce$459.82 - $587.09
($543.11)
$ 372.83-31%Reduce -35.76%1,378
REGNKen Fisher 2015-12-31 Add$459.82 - $587.09
($542.9)
$ 372.83-31%Add 22.02%615
REGNVanguard Health Care Fund 2015-09-30 Reduce-0.32%$451.82 - $592.4
($537.03)
$ 372.83-31%Reduce -11.45%2,447,894
REGNRon Baron 2015-09-30 Reduce$451.82 - $592.4
($537.03)
$ 372.83-31%Reduce -0.21%7,463
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RYAN ARTHUR FDirector 2016-11-15Sell2,000$429.34-13.16view
GOLDSTEIN JOSEPH LDirector 2016-11-14Sell2,125$450-17.15view
GOLDSTEIN JOSEPH LDirector 2016-07-29Sell2,125$425-12.28view
Sanofi10% Owner 2016-06-14Buy64,731$363.862.47view
RYAN ARTHUR FDirector 2016-05-24Sell1,000$396.64-6view
Van Plew Daniel PEVP & General Mgr Industrial O 2016-05-18Sell4,413$385.77-3.35view
GOLDSTEIN JOSEPH LDirector 2016-04-06Sell2,000$425-12.28view
GOLDSTEIN JOSEPH LDirector 2016-03-21Sell2,000$375-0.58view
Sanofi10% Owner 2016-02-17Buy161,157$392.46-5view
Sanofi10% Owner 2016-01-12Buy83,938$465.04-19.83view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Take a Look at Sanofi Oct 05 2016 
3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions Aug 14 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 

More From Other Websites
Here’s Our Take On Horizon Pharma PLC (HZNP)’s Fall Out And Regeneron Pharmaceuticals Inc... Dec 09 2016
EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA Dec 09 2016
Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key Dec 08 2016
EU Regulators Will Review Regeneron's Eczema Drug Dec 08 2016
3:36 am Regeneron Pharma and Sanofi (SNY) report EMA to review... Dec 08 2016
EU regulator accepts Sanofi/Regeneron's Dupixent product for review Dec 08 2016
Sanofi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab)... Dec 08 2016
Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab)... Dec 08 2016
Trump Talk Moves Market Again — Who Is It This Time? Dec 07 2016
Hedge Funds Are Dumping Regeneron Pharmaceuticals Inc (REGN) Dec 07 2016
The Zacks Analyst Blog Highlights: Booz Allen Hamilton Holding, McDonald's, Regions Financial and... Dec 07 2016
Play the Trump Factor with these 4 Large-Cap Stocks Dec 06 2016
Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age Dec 02 2016
Amgen, Regeneron 2017 LDL-Busters Could Boost This Small-Cap Biotech Dec 02 2016
The Numbers Behind a Pharma CEO Shouting Match Dec 02 2016
Pharma CEOs got into a heated debate over why people hate the industry Dec 01 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016
Pharma execs weigh in on possible changes under Trump Dec 01 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)